A comprehensive model of allergic rhinitis in guinea pigs.
BACKGROUND
The economic and social impact of allergic rhinitis is substantial. The effectiveness of currently available medications is limited and therefore investigations for more effective drugs is essential. This study was intended to establish a model of allergic rhinitis in guinea pigs that can be utilized for further investigation of new drugs.


METHODS
Male Dunkin Hartley guinea pigs were sensitized intranasally to, and challenged with, ovalbumin. Sneezing (SN) and nose rubbing (NR) response to allergen challenge were observed on day 21 post-initiation of sensitization in conscious guinea pigs. Nasal blockade (NB), leukocyte infiltration, and lung inflation pressure (LIP) were assessed in the same guinea pigs 23-28 days post-initiation of sensitization. A ventilator/flow method was used to measure NB and LIP. Leukocyte infiltration into nasal lavage fluid 60 min after challenge in the same animals was recorded as total and differential cell counts.


RESULTS
Sensitized guinea pigs produced acute allergic responses after allergen challenge. This was characterized by increases in SN, NR, NB, and eosinophil infiltration. In addition, intranasal allergen challenge did not change lung inflation pressure.


CONCLUSIONS
Allergen-induced rhinitis in guinea pigs resembles that in humans. The model reported in this study can be used to reflect the effectiveness of drugs currently used to treat allergic rhinitis and to investigate new potential drugs for the treatment of allergic rhinitis.
Al Suleimani
M
M
Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada V6T 1Z3.
Ying
Dong
D
Walker
Michael J A
MJ
D000818:Animals; D001794:Blood Pressure; D004195:Disease Models, Animal; D006168:Guinea Pigs; D019570:Inhalation Exposure; D008170:Lung Compliance / Q000276:immunology; D008297:Male; D009296:Nasal Cavity / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology*; D015508:Nasal Obstruction / Q000209:etiology / Q000503:physiopathology*; D010047:Ovalbumin / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D011312:Pressure; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000503:physiopathology*; D012912:Sneezing / Q000276:immunology
D010047:Ovalbumin